2012 Clinical Trials Forum

Friday, April 27, 2012
12:00 p.m. – 1:30 p.m.

This midday seminar covers important clinical topics submitted to the AAN Annual meeting and identified from other society meetings. The latest updates within several clinical trials conducted over the course of the last year will be presented with an open panel discussion at the conclusion.

This session will cover the following scientific topics.

12:00 p.m. – 12:15 p.m.
Fred Lublin, MD, FAAN
"The CombiRx Trial: A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Participants with Relapsing-Remitting Multiple Sclerosis – Clinical Outcomes"

12:15 p.m. – 12:30 p.m.
Horacio Kaufmann, MD, FAAN
"Treatment of Neurogenic Orthostatic Hypotension with Droxidopa: Results from a Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Induction Design Study"

12:30 p.m. – 12:45 p.m.
Shunichi Homma, MD
"Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial"

12:45 p.m. – 1:00 p.m.
Carol Koski, MD
"Efficacy, Safety, and Tolerability of Intravenous Gammaglobulin in a Phase 3, Randomized, Placebo-Controlled, Cross-Over Trial for the Treatment of Multifocal Motor Neuropathy (MMN)"

1:00 p.m. – 1:15 p.m.
Mark S. Forman, MD, PhD
"The Novel BACE Inhibitor MK-8931 Dramatically Lowers CSF Aβ Peptides in Healthy Subjects: Results from a Rising Single Dose Study"

1:15 p.m. – 1:30 p.m.
Open panel with speakers and closing remarks